Stock Gumshoe specializes in “sleuthing out” the investments being teased and tracking them to see, over time, whether it would have made sense to buy stocks based on the teaser ads they received. In addition to newsletter analysis, the financial blog provides contributor content, premium content to subscribers, and a lively community that actively contributes valuable comments.
Travis, Have you or any of your other ”irregulars” had anything good come from this system. I just came across it, and it certainly fits into the ”if it sounds too good to be true, it probably is” category. This gent is trying to get subscribers to pay him approx $2000/yr for a ”V” score […]
Travis! I want to challenge anyone, yourself included, who can come up with a better stock than MAIN in respect total return performance (including dividends reinvested) over 5 and 10 years. It pays 12 monthly plus 2 special semiannual dividends putting the Einstein 8th wonder of the world called “Compounding” into action. Caveat no AMZN […]
So… anything happen this week? 🙂 We’ll start with a few headline-grabbers from the Real Money Portfolio in the technology world, slide into a little teaser solution for you, and then share some updates on a couple small buys I made, plus some additions to the watchlist, along with the usual blather… Xilinx (XLNX) had […]
So I’m sure many of you have heard Stansberry pounding the drum that they are joining with Jim Rogers to predict the next CRASH. They went all in, as this time the push was advertised on CNBC, XM Radio and more. They promised to give the ”best bear market stock to own” for free at […]
The Street Authority is interviewing James Butts. The header on the video states, MiracleBlood is coming to a doctor’s office soon. He will reveal the companies heading this new treatment in his Top Stock Advisor for $199 per year. Any thoughts??
Doc Gumshoe is not in the habit of contradicting the conclusions, backed by research, that are stated in papers published by the Journal of the American Medical Association, commonly referred to as JAMA. JAMA is, after all, one of a handful of the most prestigious medical journals on the planet, along with the New […]
I’ve got a new buy to go into in some detail today, but first let’s go through some meaningful earnings reports that shook up the Real Money Portfolio this week and sent some questions my way… The Trade Desk (TTD) beat the analyst expectations for both revenue and earnings this quarter, but not in a […]